- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07780383
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: First line of the email MUST contain NCT # and Site #.
Estude backup de contato
- Nome: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Número de telefone: 855-907-3286
- E-mail: Clinical.Trials@bms.com
Locais de estudo
-
-
California
-
Anaheim, California, Estados Unidos, 92801
- Recrutamento
- CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
-
Contato:
- Amina Haggag, Site 0001
- Número de telefone: 714-774-7777
-
-
Florida
-
Bradenton, Florida, Estados Unidos, 34205
- Ainda não está recrutando
- Local Institution - 0003
-
Contato:
- Site 0003
-
Daytona Beach, Florida, Estados Unidos, 32117
- Ainda não está recrutando
- Local Institution - 0005
-
Contato:
- Site 0005
-
Naples, Florida, Estados Unidos, 34105
- Ainda não está recrutando
- Local Institution - 0007
-
Contato:
- Site 0007
-
The Villages, Florida, Estados Unidos, 32162
- Ainda não está recrutando
- Local Institution - 0006
-
Contato:
- Site 0006
-
-
Georgia
-
Decatur, Georgia, Estados Unidos, 30030
- Ainda não está recrutando
- Local Institution - 0004
-
Contato:
- Site 0004
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Participants must have a BMI of 18.0 to 35.0 kg/m2.
- For Parts A and B: Participants must be healthy as determined by medical history, Physical Examination (PE), neurological examination, vital signs, 12-lead ECG, Columbia Suicide-Severity Rating Scale (C-SSRS), and clinical laboratory evaluations.
- For Part C: Participants must meet diagnostic criteria for MCI or mild AD dementia, consistent with the National Institute on Aging and the Alzheimer's Association (NIA-AA) diagnostic criteria.
- For Part C: Participants must have an Mini Mental State Examination (MMSE) score of ≥ 20 to 28 (inclusive).
- For Part C: Participants must have evidence of positive plasma pTau217.
Exclusion Criteria
- For Parts A and B: Participants must not have a general history of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
- For Parts A and B: Participants must not have donated or lost 500 mL blood or more within 60 days prior to study intervention administration.
- For Part C: Participants must not have a neurological condition that in the opinion of the investigator may be contributing to cognitive impairment aside from the AD diagnosis, including but not limited to: Parkinson's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, long COVID, or baseline intellectual disability.
- For Part C: Participants must not have any current primary psychiatric diagnosis (eg, major depression, schizoaffective disorder or bipolar disorder) other than AD or symptoms (eg, hallucination or delusions).
- Other protocol-defined Inclusion/Exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Panel A1: BMS986446
|
Specified dose on specified days
Outros nomes:
|
|
Experimental: Panel A2: BMS986446
|
Specified dose on specified days
Outros nomes:
|
|
Experimental: Panel A3: BMS986446
|
Specified dose on specified days
Outros nomes:
|
|
Experimental: Panel B1: BMS986446
|
Specified dose on specified days
Outros nomes:
|
|
Experimental: Panel B2: BMS986446
|
Specified dose on specified days
Outros nomes:
|
|
Experimental: Panel C1: BMS986446
|
Specified dose on specified days
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusion
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Maximum observed concentration (Cmax)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Time of maximum observed concentration (Tmax)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
AUC(INF)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Half-life (T-HALF)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent total body clearance in SC administration (CLT/F)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Total body clearance in IV infusion (CLT)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Apparent volume of distribution of terminal phase in SC administration (Vz/F)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
Volume of distribution of terminal phase (VZ)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse events (AEs)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Serious adverse events (SAEs)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
AEs reported as related to BMS-986446
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Incidence of anti-drug antibody (ADA)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for Cmax
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B1 vs Panel A3 for area under the concentration-time curve (AUC)
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for Cmax
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
GMR of Panel B2 vs Panel A3 for AUC
Prazo: Up to approximately 5 months
|
Up to approximately 5 months
|
|
|
Local tolerance evaluation
Prazo: Up to approximately 5 months
|
This evaluation will assess pain, itching, burning, pressure, and soreness/tenderness (using a Numeric Rating Scale) at the injection site location. |
Up to approximately 5 months
|
|
Cmax
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Tmax
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
AUC(0-T)
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(0-672)
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
AUC(INF)
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2 |
Up to approximately 5 months
|
|
T-HALF
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
CLT/F
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Vz/F
Prazo: Up to approximately 5 months
|
Panel B1, Panel B2, Panel C1 |
Up to approximately 5 months
|
|
Trough observed plasma concentration (Ctrough)
Prazo: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Concentration at the end of a dosing interval (Ctau)
Prazo: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
|
Area under the concentration-time curve within a dosing interval (AUC(TAU))
Prazo: Up to approximately 5 months
|
Panel C1 |
Up to approximately 5 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Bristol-Myers Squibb, Bristol-Myers Squibb
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CN008-0028
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Prazo de Compartilhamento de IPD
See Plan Description
Critérios de acesso de compartilhamento IPD
See Plan Description
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .